Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

OncoSynergy Announces First Patient Treated in OS2966 Trial of Recurrent Glioblastoma

americanpharmaceuticalreviewMarch 10, 2021

Tag: OncoSynergy , OS2966 , BBB , glioblastoma , brain

PharmaSources Customer Service